Apeloa Pharmaceutical Co.,Ltd

SZSE:000739 Stock Report

Market Cap: CN¥16.3b

Apeloa PharmaceuticalLtd Future Growth

Future criteria checks 1/6

Apeloa PharmaceuticalLtd is forecast to grow earnings and revenue by 13.8% and 11.1% per annum respectively. EPS is expected to grow by 13.7% per annum. Return on equity is forecast to be 16% in 3 years.

Key information

13.8%

Earnings growth rate

13.65%

EPS growth rate

Pharmaceuticals earnings growth15.0%
Revenue growth rate11.1%
Future return on equity16.00%
Analyst coverage

Good

Last updated21 Apr 2025

Recent future growth updates

Earnings Miss: Apeloa Pharmaceutical Co.,Ltd Missed EPS By 9.7% And Analysts Are Revising Their Forecasts

Mar 13
Earnings Miss: Apeloa Pharmaceutical Co.,Ltd Missed EPS By 9.7% And Analysts Are Revising Their Forecasts

Recent updates

Apeloa PharmaceuticalLtd's (SZSE:000739) Weak Earnings May Only Reveal A Part Of The Whole Picture

Mar 17
Apeloa PharmaceuticalLtd's (SZSE:000739) Weak Earnings May Only Reveal A Part Of The Whole Picture

Earnings Miss: Apeloa Pharmaceutical Co.,Ltd Missed EPS By 9.7% And Analysts Are Revising Their Forecasts

Mar 13
Earnings Miss: Apeloa Pharmaceutical Co.,Ltd Missed EPS By 9.7% And Analysts Are Revising Their Forecasts

Apeloa Pharmaceutical Co.,Ltd's (SZSE:000739) Low P/E No Reason For Excitement

Feb 11
Apeloa Pharmaceutical Co.,Ltd's (SZSE:000739) Low P/E No Reason For Excitement

We Think Apeloa PharmaceuticalLtd (SZSE:000739) Can Stay On Top Of Its Debt

Jan 13
We Think Apeloa PharmaceuticalLtd (SZSE:000739) Can Stay On Top Of Its Debt

Apeloa Pharmaceutical Co.,Ltd (SZSE:000739) Looks Inexpensive But Perhaps Not Attractive Enough

Nov 09
Apeloa Pharmaceutical Co.,Ltd (SZSE:000739) Looks Inexpensive But Perhaps Not Attractive Enough

Apeloa PharmaceuticalLtd (SZSE:000739) Seems To Use Debt Quite Sensibly

Sep 30
Apeloa PharmaceuticalLtd (SZSE:000739) Seems To Use Debt Quite Sensibly

Lacklustre Performance Is Driving Apeloa Pharmaceutical Co.,Ltd's (SZSE:000739) Low P/E

Aug 07
Lacklustre Performance Is Driving Apeloa Pharmaceutical Co.,Ltd's (SZSE:000739) Low P/E

Is Apeloa PharmaceuticalLtd (SZSE:000739) Using Too Much Debt?

Jun 24
Is Apeloa PharmaceuticalLtd (SZSE:000739) Using Too Much Debt?

Apeloa Pharmaceutical Co.,Ltd's (SZSE:000739) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

May 08
Apeloa Pharmaceutical Co.,Ltd's (SZSE:000739) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Earnings and Revenue Growth Forecasts

SZSE:000739 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202715,8511,5217572,0084
12/31/202614,3351,3614011,8557
12/31/202513,0951,1931,0592,1317
3/31/202511,5541,036523914N/A
12/31/202412,0221,0317481,209N/A
9/30/202412,2641,0747641,349N/A
6/30/202411,9481,0796361,270N/A
3/31/202411,5871,0604541,089N/A
12/31/202311,4741,0554011,031N/A
9/30/202311,4941,1837841,304N/A
6/30/202311,5141,1531,3831,740N/A
3/31/202311,5291,0768991,377N/A
1/1/202310,5459898171,326N/A
9/30/202210,094851326822N/A
6/30/20229,651839-140617N/A
3/31/20229,077890-160635N/A
1/1/20228,943956-90612N/A
9/30/20218,468949-35722N/A
6/30/20218,165941180738N/A
3/31/20218,1468796751,048N/A
12/31/20207,8808177421,060N/A
9/30/20207,6067521,1561,276N/A
6/30/20207,6537021,4191,471N/A
3/31/20207,2365981,2821,340N/A
12/31/20197,2115531,3281,360N/A
9/30/20197,1225291,2581,316N/A
6/30/20196,8554659661,029N/A
3/31/20196,605414714811N/A
12/31/20186,376371N/A833N/A
9/30/20186,246367N/A523N/A
6/30/20185,882313N/A425N/A
3/31/20185,674275N/A410N/A
12/31/20175,552257N/A210N/A
9/30/20175,313253N/A465N/A
6/30/20175,312279N/A307N/A
3/31/20175,112274N/A304N/A
12/31/20164,772263N/A180N/A
9/30/20164,476201N/A223N/A
6/30/20164,349190N/A304N/A
3/31/20164,284198N/A255N/A
12/31/20154,338208N/A441N/A
9/30/20154,195231N/A580N/A
6/30/20154,219236N/A642N/A
3/31/20154,281241N/A750N/A
12/31/20144,233322N/A787N/A
9/30/20144,112313N/A435N/A
6/30/20144,100305N/A391N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 000739's forecast earnings growth (13.8% per year) is above the savings rate (2.7%).

Earnings vs Market: 000739's earnings (13.8% per year) are forecast to grow slower than the CN market (23.5% per year).

High Growth Earnings: 000739's earnings are forecast to grow, but not significantly.

Revenue vs Market: 000739's revenue (11.1% per year) is forecast to grow slower than the CN market (12.4% per year).

High Growth Revenue: 000739's revenue (11.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 000739's Return on Equity is forecast to be low in 3 years time (16%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/22 15:14
End of Day Share Price 2025/05/22 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Apeloa Pharmaceutical Co.,Ltd is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Wanhua WuChina International Capital Corporation Limited
Kai WangCitic Securities Co., Ltd.
Siyu PengGuosen Securities Co., Ltd.